Cost-effectiveness of digital mammography compared to film mammography in screening of breast cancer: a systematic review

Aziz Rezapour, Hossein Bouzarjomehri, Akhtar Shah-Savandi, Emad Karimianrad, Narges Pirani, Jalal Arabloo, Samira Soleimanpoor, Yasaman Herandi

Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran

Abstract

Background: Mammography as the best method of diagnosing breast cancer in its early stages has been accepted in many countries. Digital mammography is in development and is used in breast cancer screening in countries such as the United States, however, cost-effectiveness of digital mammography screening (DMS) compared to film mammography screening (FMS) is debatable. This study is designed to systematically review the available evidence in this regard.

Methods: This study is designed as a systematic review using PRISMA guidelines. The search was conducted on October 2019 on the PubMed, Web of Science core collection, Embase, Scopus, Cochrane library and ProQuest databases. All full economic evaluation studies (cost-effectiveness analysis (CEA), cost-utility analysis (CUA), and cost-benefit analysis (CBA)) that assessed DMS compared to FMS are included. The quality of final articles were evaluated by CHEERS checklist and data was collected using a data extraction form. Finally, the data was analyzed by a meta-synthesis method.

Results: Five studies were included. Three of them were conducted in the U.S., one in the Australia, and one the Brazil. Studies show that despite the slight difference in the effectiveness of DMS, its costs increased more. Three studies concluded that age-targeted DMS and FMS might be cost-effective and two concluded biennial DMS might be cost-effective digital strategy, however one study concluded that biennial FMS is still cost-effective.

Conclusion: There is currently little evidence on the cost-effectiveness of DMS over FMS and more evidence is needed, especially in developing countries. While the cost-effectiveness of DMS has not been fully confirmed, manufacturers are developing digital mammography; on the other hand, film mammography is obsoleting. Therefore, the move towards digital mammography, especially in developing countries, should be gradual and targeted.

Keywords: digital mammography, screening, breast cancer, economic evaluation, systematic review

Introduction

Due to social and industrial changes and epidemiological transition, the pattern of diseases has changed, shifting from infectious diseases to chronic diseases such as cancers\(^1\). Among the cancers, breast cancer is the most common cancer in women and is the leading cause of death in women aged 40 to 45 years. Breast cancer accounts for 32% of all cancers, and in general, 19% of women die from cancer\(^2\). The incidence rate of breast cancer is one in nine women in United States, one in twelve in the United Kingdom and one in thirteen in Australia\(^3\). According to the Global Burden of Disease study in 2016, annually breast cancer had the highest incidence rate of all cancers in women (1.7 million), accounting for 535,000 deaths and about 15 million disability-adjusted life years (DALYs). Also, for adults (20 to 39 years old), the most common cancer in the world is breast cancer, and in total, it was the third most common cancer among all cancers\(^4\). According to the World Health Organization report, 508,000 women died of breast cancer in 2011, and the number of annually new cases is expected to increase from 10 million to 15 million by 2020\(^5\).

One of the most effective ways to reduce the risk of breast cancer and increase the life expectancy of patients is early detection of the disease by screening methods. Studies show that early detection will increase the life expectancy of more than 90 percent of cancer patients\(^6\). Breast cancer can be detected early by regular self-examination or physical examination by a doctor or midwife\(^7\), however, the mammography is considered the best method for screening and diagnosing of breast cancer in early stages in most countries around the world\(^8\) due to its 80 to 85% sensitivity for diagnosis of breast masses\(^9\).

As new technologies are changing from analog to digital, mammography is no exception. Digital mam-
mography, as an alternative choice to film mammography, has the innate advantage of digital technologies, however its cost-effectiveness for breast cancer screening is still controversial. Different results were observed in studies comparing effectiveness of film mammography with digital mammography. Some studies expressed relatively equal effectiveness for both technologies while some studies have considered digital mammography to be more effective in certain age groups. In Carney and Kerlikowske’s study, the sensitivity of digital mammography was significantly higher in women under 50 years old, women with extremely dense breast, women with entirely fatty breast density and pre- or peri-menopausal women, however film mammography had a higher sensitivity in women upper 50 years old. Similarly, in Pisano study, the sensitivity of digital mammography in screening and diagnosis of breast cancer was significantly higher in women under 50 (78 vs. 51) and had a similar advantage in premenopausal women and women with dense breasts. These findings have been confirmed in other studies.

Modern technologies have introduced digital mammography devices to global market, which their higher accuracy in diagnosis comes with higher costs. Although there are studies comparing effectiveness or cost-effectiveness of digital mammography versus film mammography in screening of breast cancer, there is no systematic review of cost-effectiveness studies. Therefore, this study is designed to review the evidence on cost-effectiveness of digital mammography screening (DMS) compared to film mammography screening (FMS).

Methods

This systematic review and meta-synthesis assessed the existing evidences until October 2019 using PRISMA guidelines. Its protocol is registered at the PROSPERO system under the code number of CRD42019139131 and ethical clearance is obtained from the authors institute research ethics committee under the code number of IR.IUMS.REC.1398.388. In order to conduct the systematic review, the structured components of PICOS defined as first author name, publication year, country, reference year, population, effectiveness criteria, study perspective, type of used model, costs and expenses, cost-effectiveness results, sensitivity analysis methods and results, and final conclusion. Two researchers were responsible for extracting data.

Data extraction

In order to prepare data extraction tool, the instrument that introduced in the study of Wijnen et al was used. For each included study a sheet was created in Microsoft Excel software containing the studies’ information such as first author name, publication year, country, reference year, population, effectiveness criteria, study perspective, type of used model, costs and expenses, cost-effectiveness results, sensitivity analysis methods and results, and final conclusion. Two researchers were responsible for extracting data.

Data analyzing

The final data was analyzed through meta-synthesis methods. In order to prevent bias, the whole process of search to data analysis was carried out by two researchers independently under the supervision of an advisor.
**Results**

Five papers were selected (Table 1, 2). Three of which were conducted in the U.S.\(^{20-22}\), one in Australia\(^{13}\), and one in Brazil\(^{23}\). Quality assessment with CHEERS checklist shows scores of about or over 80% for all of studies and they are of fine quality. Two studies were from the perspective of Society\(^{13, 20}\), two from the federal payer\(^{20, 21}\), and two from health system\(^{22, 23}\). Studies have been published from 2008 to 2015 (Table 1).

**Modeling**

Three of studies which were conducted in the U.S. had used models from the Cancer Intervention and Surveillance Modeling Network (CISNET)\(^{20-22}\). Tosteson et al. employed a discrete-event simulation model as a CISNET\(^{24}\). Stout et al. have used five CISNET models\(^{24-28}\). Ravesteyn et al. used two models of MISCANFadia (Microsimulation SCreening Analysis—Fatal Diameter) and SPECTRUM (Simulating Population Effects of Cancer Control inTerventions—Race and Understanding Mortality) which were developed independently within the CISNET\(^{27, 28}\). Wang et al. used a study based model\(^{13}\) and Souza and Polanczyk used the Markov model\(^{23}\).

**Costs and outcomes measures**

Studies included fixed, variable and semi-variable costs of DMS and FMS into the analysis for the base year of 2005\(^{20}\), 2007\(^{13}\), 2010\(^{22}\), 2011\(^{22}\), and 2012\(^{21}\). For outcomes, three studies used quality adjusted life years gained (QALY)\(^{20, 21, 23}\), two of them used life years gained (LYG) and death averted or mortality reduction\(^{21, 22}\), and one only used the number of additional cancers detected which is an intermediate output\(^{13}\).

**Compared strategies**

Studies compared different strategies and had up to ten strategies for comparison. Three of them compared annual and biennial DMS with FMS\(^{20-23}\), three evaluated DMS for populations with dense breast\(^{13, 20, 21}\), all studies examined age-targeted strategies and one study examined strategies for different American races (black, white and Hispanic)\(^{22}\).

**Cost-effectiveness**

Studies have reported their results in different ways that makes it hard to aggregate them. Three studies concluded that age-targeted DMS and FMS for older population might be cost-effective\(^{13, 20, 22}\) and two concluded biennial DMS might be cost-effective digital strategy\(^{21, 22}\), however one study that conducted in the Brazil conclud-
Table 1 Included Studies

| Title                                                                 | First author               | Year | Journal                                           | Country | Perspective | Target population | Study type | Conflict of interests | CHEERS quality assessment score (%) |
|----------------------------------------------------------------------|----------------------------|------|---------------------------------------------------|---------|--------------|-------------------|------------|-----------------------|--------------------------------------|
| Transition from film to digital mammography: Impact for breast cancer screening through the national breast and cervical cancer early detection program | Nicolien T. van Ravesteyn  | 2015 | American Journal of Preventive Medicine           | U.S     | Not mentioned - but it seems to be health system | Women aged 40–64 in 2010 | CEA        | No                    | 79.54                                |
| Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography | Natasha K. Stout           | 2014 | Journal of the National Cancer Institute          | U.S     | Federal payer | Woman 50–47 y in 2001–2008 | CEA, CUA   | No                    | 89.13                                |
| Is Age-targeted full-field digital mammography screening cost-effective in emerging countries? A micro simulation model | Fabiano Hahn Souza        | 2013 | SpringerPlus                                     | Brazil   | Health system | Woman between 40 to 49 years in 2010 | CUA        | No                    | 93.5                                 |
| Cost and cost-effectiveness of digital mammography compared with film-screenmammography in Australia | Shuhong Wang               | 2009 | Australian and New Zealand Journal of Public Health | Australia | Society | Woman <50 y Pre- or peri-menopausal women, Women with heterogeneously or extremely dense breasts in 2007 | CEA        | No                    | 95.65                                |
| Cost-effectiveness of digital mammography breast cancer screening        | Anna N.A. Tosteson         | 2008 | Annals of internal medicine                      | U.S     | Society and Medicare | Women age 40 years or older in 2000 | CUA        | No                    | 100                                 |

Table 2 Extracted data from studies

| First aut., yr (ref.) | Analytic models                                                                 | Discount rate | Interventions / Strategies                                                                 | Cost per outcome                                                                 | Uncertainty/ Sensitivity analysis |
|-----------------------|--------------------------------------------------------------------------------|---------------|------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|----------------------------------|
| Ravesteyn, 2015 (22)  | MISCAN Fadia, SPECTRUM                                                          | Not mentioned, 2010 US$ | Annual FMS vs Annual DMS with fixed no. of mmg, Annual DMS with fixed budget, Biennial DMS with fixed budget | Cost per LYG, US$: 1. 182,558 to 415,000 (LYG 2%-4% increases and costs 34.0%-34.7% increases) 2. LYG 22%-24% decreases 3. LYG 8%-13% increase 4. LYG 16%-17% increase | Multiple sensitivity analyses |
| Stout, 2014 (21)       | Five CISNET models                                                              | 5%, 2012 US$  | 1. No screening, 2. FMS biennial 50 to 74 years, 3. DMS biennial 50 to 74 years, 4. DMS biennial from ages 40 to 74 years, 5. DMS annual from ages 50 to 74 years, 6. DMS annual from ages 40 to 49 years followed by biennial from ages 50 to 74 years, 7. DMS annual from ages 40 to 49 years for those with dense breast tissue and biennial screening otherwise | Cost per QALY’s, US$: 1. 175000 Efficient Digital Strategies: 4. 33,200 to 113,300 5. 39,300 to 264,700 6. 74,400 to 582,000 | One-way sensitivity analyses |
| Souza, 2013 (23)       | Markov model                                                                    | 5%, 2010 Brazilian Real (R$) | 1. Usual care, 2. Annual FMS, 3. Biennial FMS, 4. Annual DMS, 5. Biennial DMS, 6. Annual DMS (≤50) and FMS (50–69), 7. Annual DMS (≤50) and biennial FMS (50–69) | Cost per QALY’s, R$: 1. 1,509; 2. 13,131; 3. 30,520; | One-way sensitivity analysis |
| Wang, 2009 (13)        | Study base                                                                       | 5%, 2007 Australian Dollars (AUS) | DMS vs FMS in Woman under the age of 50 years, Pre- or peri-menopausal women, Women with radiographically dense breasts | Cost per extra cancer detected, AUS$: 1. 10,364 [6,333, 28,500] 2. 8,143 [5,182, 19,000] 3. 10,364 [6,000, 57,000] | One-way sensitivity analyses |
| Tosteson, 2008 (20)    | Validated, discrete-event simulation model as a CISNET                           | 3%, 2005 US$  | Women age >40 y: base case, 1. All-film, 2. Age-targeted digital, 3. Age- and density-targeted digital, 4. All-digital Women age >65 y: base case, 5. All-film, 6. Density-targeted digital, 7. All-digital Women age >65 y: alternative case, 8. All-film, 9. Density-targeted digital, 10. All-digital | Cost per QALY, US$: 1. 26,500 (21,000–33,000) 2. 84,500 (75,000–93,000) Dominated | One-way sensitivity analyses |
ed that biennial FMS is still cost-effective. The study of Tosteson et al. shows that lowest ICER level yield from age-targeted DMS which is US$26500. Based on that, age-targeted DMS is recommended, however the rest of DMS strategies considered not cost-effective.

Wang et al. concluded that the ICER of DMS compared to FMS in women under the age of 50 and women with heterogeneous breasts was AU$10,364, and in pre-or postmenopausal women was AU$8143; however, they recommended DMS for women under the age of 50, and FMS for older women.

Souza and Polanczyk showed that the biennial FMS with ICER of RS1509 is still cost-effective especially in developing countries. However, due to geographical differences in large countries, the use of DMS as an age-target in areas with a higher incidence of breast cancer (such as southern Brazil) may be recommended.

The study of Stout et al. found that biennial DMS was slightly more effective than film (average 1% reduction in mortality and 7% more QALY (equivalent to 2 years)) but also had higher costs (about 11% increase in costs) and its ICER will be US$175,000. Among the most effective DMS strategies were biennial DMS for 40–74 years old women and DMS for 40–74 years old women with dense breast tissue and biennial DMS for others. The ICER of these strategies varied between the five used models (Table 2). This study shows that changes from film to digital mammography increased costs but have little effects, especially for women aged 40–49.

The findings of study of Ravesteyn et al. estimate that 32,9721 film mammograms were performed in 2010 to prevent 106-136 deaths, and that 1948–2305 years of life were gained. If this number of mammograms were done digitally, it would prevented 111–138 deaths and gained 2034–2345 years of life, which means a 2–4% increase in effectiveness but also higher costs (34–35%). Assuming a fixed budget, by shifting from FMS to DMS, 25–26% less women can receive mammograms. This leads to a 23–24% increase in breast cancer mortality and a 22–24% decrease in LYG. The use of fixed-budget DMS on a biennial basis continues to provide fewer mammography services to women, but the benefits of each mammogram for biennial screening outweigh the annual screening to 8–13% increase. In addition, if biennial screening is restricted to women over the age of 50, LYG is increased by 17–16%. The study concludes that with a fixed budget, fewer women with less LYG may be less likely to be served. Changes in the screening program, including only having biennial screening, increase LYG/screening rates, and can compensate for the potential reduction in LYG when transferring to digital mammography.

Sensitivity analysis

Four studies used one-way sensitivity analysis and one study, used multiple sensitivity analysis. The results were most sensitive to the costs of DMS, the prevalence of dense breast, throughput of a mammography system, and opportunistic screening coverage. If the cost of DMS is equivalent to FMS, the development of digital mammography will be more cost-effective.

Discussion

In Western countries, mammography screening has been set as a standard for early detection of breast cancer. Some studies presented the cost-effectiveness of FMS in Western countries, however, its benefits in developing countries remains under question. In addition, due to diagnostic value of digital mammography, especially for women of young age and women with high dense breasts, it is being developed day by day and is used for breast cancer screening in developed countries such as the U.S. Zegordi et al. carried out a systematic review comparing effectiveness of DMS with FMS, claiming that DMS is more effective, therefore suggested DMS even for developing countries. However, the effectiveness studies did not consider the extra costs of DMS. While digital mammography devices, have proven to be more accurate in diagnosis, they come at higher costs.

Although there are few and heterogeneous studies on cost-effectiveness of DMS compared to FMS, and there is a lack of sufficient data for decision making in many countries, especially developing countries, as a general conclusion from the available studies, the results of this systematic review similarly indicates that like other studies, DMS is more effective; However, despite the slight difference in effectiveness, the additional costs of DMS significantly increase. Still, DMS may be cost-effective in certain cases such as women aged 40–49 years (age-targeted strategies), regions where breast cancer is more common, and biennial strategies and women with extremely dense breasts. Although, the increase of false positive diagnoses in DMS results in reduced effectiveness, and subsequently DMS may not be cost effective anymore. In case of misdiagnosis, failing to account the QALY lost and future additional costs, is one of the limitations of found studies and making more accurate judgments is not possible. These unwanted and hidden costs must be considered before using new technologies.

Digital mammography as an alternative to film mammography, despite having hidden costs, also has the innate advantages of digital technologies, hence its overt and covert advantages must be taken into account. In addition, the film mammography devices are no longer technically developed by manufacturers and will become obsolete over time. Many of the digital mammography advantages cannot be measured in economic evaluation studies. First, due to reduced supports for film mammography equipment, the costs of film mammography may
increase over time in the near future. Second, although the average time spend in digital mammography process is longer than film mammography, the access to digital images through the PACS system in different medical centers will increase, which leads to minimization of traveling time; therefore, flexibility and efficiency will increase. In addition, by development of tele-mammography, the cost of film transferring to diagnostic centers is reduced. Third, technological advances and post-process imaging ability of digital mammography may be able to reduce the plausible need for repeating the mammography\(^{35}\). This can lead to economic savings especially for rural women and people who are distant from imaging center. Finally, digital mammography may reduce absorbed dose for patients. This matter can even benefit the health and safety of healthcare staff by making their job easier and less exposed to hazardous chemicals.

At last, it should be mentioned that four out of five studies have been conducted in developed countries, which three of them have been in the United States. However, these studies have not confirmed the cost-effectiveness of annual DMS for all age groups, rather they considered DMS to be cost-effective for extremely dense breasts, for specific age groups or for biennial strategies and the cost-effectiveness of DMS is still questionable for developed countries like the United States. The only study conducted in developing countries, concluded that DMS is not cost-effective. Therefore, although developed countries are moving towards digital mammography, developing countries should be more careful in this transition. Developing countries, due to their weak regulations, may be more vulnerable to the marketing of medical equipment companies and they should be more careful in applying new technologies, as due to the inevitable risk of induced demand, limiting access for new technologies to certain age groups or certain physical conditions (such as breast density) could be struggling\(^{35}\). Accordingly, the whole costs and advantages of digital mammography should also be considered, especially since the costs of digital mammography will decrease over time\(^{36-38}\). Therefore, moving towards digital mammography, particularly in developing countries, should be gradual.

**Conclusion**

In regard to making an evidence-based decision on breast cancer screening by mammography, there is a need for more specific studies especially for developing countries. Existing studies show that DMS might be cost-effective under certain conditions such as biennial or age-targeted DMS or DMS for women with dense breast or in regions with high incidence of breast cancer. In other conditions such as annual screening and older women the FMS might be more cost-effective. It is considerable that four out of five studies were from developed countries and the only study that evaluated DMS in a developing country concluded that FMS is more cost-effective. Whilst this study did not confirm the DMS for all conditions, it shows that moving towards digital technologies may be inevitable in future, therefore it is recommended to apply digital mammography gradually.

**Limitations:**

Although the reviewed studies were of high quality, it must be noted that this study confronted with number of limitations including lack of studies particularly in developing countries. Existing studies did not covered all the costs and advantages of digital mammography. Therefore, further studies in this field seems to be necessary in developing countries.

**Acknowledgement:**

This work was funded and supported by the Healthcare Management and Economics Research Center of Iran University of Medical Sciences [grant number 98-1-48-15056]. The authors would like to express their sincere gratitude to this research center for their support and invaluable guidance and encouragement.

**Conflict of interest:**

The Authors declare that they have no conflict of interest.

**References**

1) Mercer A. (2014) Infections, chronic disease, and the epidemiological transition: a new perspective. Boydell & Brewer. isbn: 1580465080.

2) Danesh A, Amiri M, Zamani A, Tazhibi M, Ganji F. (2002) Knowledge, attitude and practice (KAP) rate of women employees of education organization about breast self-examination, Shahrekord, 1998. J Shahrekord Univ Med Sci. 4(2): 47–52. [In Persian]

3) Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alisharif U, Alvis-Guzman N, Amini E, Anderson BO. (2018) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA oncol. 4(11): 1553–68. [In Persian]

4) Naghibi A, Jamshidi P, Yazdani J, Rostami F. (2016) Identification of Factors Associated with Breast Cancer Screening Based on the PEN-3 Model among Female School Teachers in Kermanshah. Iran J Health Educ Health Promot. 4(1): 58–64. [In Persian]

5) Neyerstani H, Vafaee-Najjar A, Ebrahimpour H, Shams M, Esmaeili H, Nikparast N, Nosrati M. (2013) Mammography in Rural Areas of Iran: A Qualitative Study for Designing a Social Marketing Intervention. J Qual Res Health Sci. 2(2): 173–83. [In Persian]

6) Akbari M, Mirzaei H, Soori H. (2006) 5 year survival of breast cancer in Shohada-e-Taqhtis and Jorjani hospitals. Hakim Research Journal. 9(2): 39–44. [In Persian]

7) Hatenefia E, Niknami S, Mahmoudi M, Ghofranipour F, Lamyian M. (2010) The effects of health belief model education on knowledge, attitude and behavior of Tehran pharmaceutical industry employees regarding breast cancer and mammography. Behbod Journal. 14(1). [In Persian]

8) Abedini M, Kaviani A, Allameh M, Esmaeili M, Motall M. (2010) Breast diseases: clinical exam and diagnosis methods for physicians and health workers of health centers. Tehran, Iran: Mezrab. [In Persian]

9) Zegordi BS, akbari-sari A, Ravaghi H, bordbar A, Moradi-joo M, Arian-khesal A. (2015) Comparing the Effectiveness of Digital and Analog Mammography in Breast Cancer Diagnosis and Screening: A Systematic Review and Meta-Analysis. Journal of
10) Carney PA, Miglioretti DL, Yankaskas BC, Kerlikowske K, Rosenberg R, Rutter CM, Geller BM, Abraham LA, Taplin SH, Dignan M. (2003) Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Annals of internal medicine. 138(3): 168–75.

11) Kerlikowske K, Hubbard RA, Miglioretti DL, Geller BM, Yankaskas BC, Lehman CD, Taplin SH, Sickles EA. (2011) Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study. Annals of internal medicine. 155(8): 493–502.

12) Pisano ED, Hendrick RE, Yaffe MJ, Baum JK, Achariya S, Cormack JB, Hanna LA, Conant EF, Fajardo LL, Bassett LW. (2008) Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST. Radiology. 246(2): 376–83.

13) Wang S, Merlin T, Kreisz F, Craft P, Hiller JE. (2009) Cost and cost-effectiveness of digital mammography compared with film-screen mammography in Australia. Australian and New Zealand journal of public health. 33(5): 430–6.

14) Iared W, Shigueoka DC, Torloni MR, Velloni FG, Ajzen SA, Atallah AN, Valente O. (2011) Comparative evaluation of digital mammography and film mammography: systematic review and meta-analysis. Sao Paulo Medical Journal. 129(4): 250–60.

15) Souza FH, Wendland EM, Rosa MI, Polanczyk CA. (2013) Is full-field digital mammography more accurate than screen-film mammography in overall population screening? A systematic review and meta-analysis. The Breast. 22(3): 217–24.

16) Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS med. 6(7): e1000097.

17) Rezapour A, Bouzarjomehri H, Shah-Savandi A, Pirani N, Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. (2009) Consolidated health economic evaluation reporting standards (CHEERS) statement. Cost Effectiveness and Resource Evaluations for informing evidence-based healthcare decisions: part 3/3. Expert Report. 403.

18) Mandelblatt J, Schechter CB, Lawrence W, Yi B, Cullen J. (2006) Mammographic performance in a population-based screening program: before, during, and after the transition from screen-film to full-field digital mammography. Jama. 296(1): 62–8.

19) Fishman P, Tosteson AN. (2012) Assessing healthcare use and cost consequences of a new screening modality: The case of digital mammography. JNCI Monographs. 2006(36): 38–41.

20) Royalty J, Miller JW, Near AM, Cronin KA, Heijnsdijk EA, Cormack JB, Hanna LA, Conant EF, Fajardo LL, Bassett LW. (2008) Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST. Radiology. 246(2): 376–83.

21) Pisano ED, Hendrick RE, Yaffe MJ, Baum JK, Achariya S, Cormack JB, Hanna LA, Conant EF, Fajardo LL, Bassett LW. (2008) Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST. Radiology. 246(2): 376–83.

22) Van Ravesteyn NT, Van Lier L, Schechter CB, Ekwueme DU, Royalty J, Miller JW, Near AM, Cronin KA, Heijnsdijk EA, Mandelblatt JS. (2015) Transition from film to digital mammography: impact for breast cancer screening through the national breast and cervical cancer early detection program. American journal of preventive medicine. 48(3): 535–42.

23) Souza FH, Polanczyk CA. (2013) Is Age-targeted full-field digital mammography screening cost-effective in emerging countries? A micro-simulation model. Springerplus. 2(1): 366.

24) Fryback DG, Stout NK, Rosenberg MA, Trentham-Dietz A, Kuruchittham V, Remington PL. (2006) Chapter 7: The Wisconsin breast cancer epidemiology simulation model. JNCI Monographs. 2006(36): 37–47.

25) Berry DA, Inoue L, Shen Y, Venier J, Cohen D, Bondy M, Theriault R, Munsell MF. (2006) Chapter 6: Modeling the Impact of Treatment and Screening on US Breast Cancer Mortality: A Bayesian Approach. JNCI Monographs. 2006(36): 30–6.

26) Lee S, Zelen M. (2006) Chapter 11: a stochastic model for predicting the mortality of breast cancer. JNCI Monographs. 2006(36): 79–86.

27) Mandelblatt J, Schechter CB, Lawrence W, Yi B, Cullen J. (2006) Chapter 8: The spectrum population model of the impact of screening and treatment on US breast cancer trends from 1975 to 2000: Principles and practice of the model methods. JNCI Monographs. 2006(36): 47–55

28) Tan SY, Van Oortmarssen GJ, De Koning HJ, Boer R, Habbema JDF. (2006) Chapter 9: the MISCAN-Fadia continuous tumor growth model for breast cancer. JNCI Monographs. 2006(36): 56–65.

29) Lindfors KK, Rosenquist CJ. (1995) The cost-effectiveness of mammographic screening strategies. Jama. 274(1): 881–4.

30) Szeto KL, Devlin NJ. (1996) The cost-effectiveness of mammography screening: evidence from a microsimulation model for New Zealand. Health policy. 38(2): 101–15.

31) Okonkwo QL, Draisma G, der Kinderen A, Brown ML, de Koning HJ. (2008) Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. JNCI: Journal of the National Cancer Institute. 100(18): 1290–300.

32) Rojnik K, Naverinik K, Mateović-Rojnik T, Primčič-Žakelj M. (2008) Probabilistic cost-effectiveness modeling of different breast cancer screening policies in Slovenia. Value in Health. 11(2): 139–48.

33) Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Achariya S, Conant EF, Fajardo LL, Bassett L, D’Orsi C. (2005) Diagnostic performance of digital versus film mammography for breast-cancer screening. New England Journal of Medicine. 353(2): 1773–83.

34) Valentijn J. (2004) Guest editorial, preface, main points, glossary and chapter 1. SAGE Publications Sage UK: London, England; p. 1–5.

35) Legood R, Gray A. (2004) A cost comparison of full field digital mammography (FFDM) with film-screen mammography in breast cancer screening. NHS Breast Screening Programme Equipment Report. 403.

36) Henderson LM, Hubbard RA, Onega TL, Zhu W, Buist DS, Fishman P, Tosteson AN. (2012) Assessing healthcare use and cost consequences of a new screening modality: The case of digital mammography. Medical care. 50(12): 1045.

37) Han M, Rim N-J, Lee JS, Kim SY, Choi JW. (2014) Feasibility of comparative evaluation of digital mammography compared to digital mammography: exploratory analysis of selected population subgroups in DMIST. Radiology. 246(2): 376–83.

38) Hofvind S, Skaane P, Elmore JG, Sebuødegård S, Hoff SR, Lee CI. (2014) Mammographic performance in a population-based screening program: before, during, and after the transition from screen-film to full-field digital mammography. Radiology. 272(1): 52–62.